{"groups":[{"description":"Participants in Arm 1 will receive elacestrant\n\nElacestrant: 400 mg/day once daily oral dosing","id":"FG000","title":"Elacestrant"},{"description":"Participants in Arm 2 will receive Investigator's choice of one of the standard-of-care drugs (fulvestrant, anastrozole, letrozole, or exemestane)\n\nStandard of Care:\n\n* Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle\n* Anastrozole 1 mg/day on a continuous dosing schedule\n* Letrozole: 2.5 mg/day on a continuous dosing schedule\n* Exemestane: 25 mg/day on a continuous dosing schedule","id":"FG001","title":"Standard of Care (SoC)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"25"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant Noncompliance"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"69"},{"groupId":"FG001","numSubjects":"79"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"239"},{"groupId":"FG001","numSubjects":"239"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"239"},{"groupId":"FG001","numSubjects":"239"}],"type":"Intent-to-Treat Population"},{"achievements":[{"groupId":"FG000","numSubjects":"237"},{"groupId":"FG001","numSubjects":"230"}],"type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"152"},{"comment":"Only deaths indicated as leading to study discontinuation are reported in the Participant Flow section. All deaths regardless of causality or whether they were reported as a reason for study discontinuation are reported in the All-Cause Mortality section.","groupId":"FG001","numSubjects":"130"}],"comment":"Only deaths indicated as leading to study discontinuation are reported in the Participant Flow section. All deaths regardless of causality or whether they were reported as a reason for study discontinuation are reported in the All-Cause Mortality section.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"109"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}